ABCG2 and hematologic disorder: Overexpression of the ABC drug transporter ABCG2 has been linked to acquired resistance to a wide range of clinically relevant anticancer agents and across multiple malignances, including non-small cell lung, thyroid, and breast cancer cells as well as hematological malignancies [21,22,23,24,25].